Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Overview
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Companies Involved in Therapeutics Development
Clayton Biotechnologies Inc
Derm-Biome Pharmaceuticals Inc
Histogen Inc
Takeda Pharmaceutical Co Ltd
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Drug Profiles
BaxB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DB-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Dormant Products
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Discontinued Products
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Product Development Milestones
Featured News & Press Releases
May 19, 2021: Histogen and Amerimmune report publication on Emricasan in COVID-19
Mar 16, 2021: Histogen and Amerimmune announce first patient dosed in phase 1 study of Emricasan in symptomatic COVID-19 patients
Oct 06, 2020: Derm-Biome Pharmaceuticals reports positive results from a preclinical study in psoriasis
Jun 24, 2019: Cotus announces results from ENCORE-LF and ENCORE-PH phase 2b clinical trials in SH Cirrhosis
Jun 24, 2019: Novartis provides update on phase 2b ENCORE-LF trial in SH cirrhosis
Apr 30, 2019: Cotus Pharmaceuticals announces publication demonstrating that Emricasan Ameliorates Portal Hypertension, improves liver structure and function in a preclinical model of advanced cirrhosis
Apr 15, 2019: Cotus late-breaker oral presentation at EASL meeting details results of ENCORE-PH phase 2b clinical trial in patients with SH cirrhosis and severe portal hypertension
Mar 21, 2019: Cotus announces top-line results from ENCORE-NF phase 2b clinical trial in SH fibrosis
Mar 13, 2019: Cotus Late-breaker oral presentation at EASL meeting to detail results of ENCORE-PH Phase 2b clinical trial in patients with SH Cirrhosis and Severe Portal Hypertension
Feb 12, 2019: Cotus announces completion of enrollment in ENCORE-LF phase 2b clinical trial of Emricasan in patients with decompensated SH cirrhosis
Jan 28, 2019: Cotus Pharmaceuticals announces publications expanding on previously reported results from completed phase 2 FLD-SH, portal hypertension and liver cirrhosis clinical trials
Dec 05, 2018: Cotus Announces Results from ENCORE-PH Phase 2b Clinical Trial in SH Cirrhosis
Oct 26, 2018: Derm-Biome Pharmaceuticals commences testing its proprietary compounds on skin microbiome targets.
Sep 20, 2018: Cotus Pharmaceuticals to Host Alyst and Investor Symposium on Portal Hypertension
Jul 02, 2018: Cotus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Clayton Biotechnologies Inc, 2021
Pipeline by Derm-Biome Pharmaceuticals Inc, 2021
Pipeline by Histogen Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021